Shares of Onconetix, Inc. (NASDAQ:ONCO – Free Report) are scheduled to reverse split on the morning of Tuesday, September 24th. The 1-40 reverse split was announced on Friday, September 20th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, September 23rd.
Onconetix Trading Down 28.7 %
Shares of ONCO traded down $0.03 during trading hours on Friday, reaching $0.08. 5,200,758 shares of the company traded hands, compared to its average volume of 6,247,411. The company’s fifty day moving average price is $0.14 and its two-hundred day moving average price is $0.15. The company has a current ratio of 0.10, a quick ratio of 0.09 and a debt-to-equity ratio of 0.08. Onconetix has a 12 month low of $0.08 and a 12 month high of $0.62.
Onconetix (NASDAQ:ONCO – Get Free Report) last announced its earnings results on Thursday, August 29th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $0.71 million for the quarter.
Institutional Inflows and Outflows
Onconetix Company Profile
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Read More
- Five stocks we like better than Onconetix
- How to Invest in Biotech Stocks
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What Are Dividend Achievers? An Introduction
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Low PE Growth Stocks: Unlocking Investment Opportunities
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.